Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vistagen Therapeutics Inc. (VTGN)
:VTGN
RESEARCH TOOLSreports
VTGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $5.74
Previous CloseN/A
Volume188.19K
Average Volume (3M)190.07K
Market Cap
$84.71M
Enterprise Value-$3.58M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Jul 01, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding28,862,085
10 Day Avg. Volume190,023
30 Day Avg. Volume190,074
Standard Deviation0.44
R-Squared0.00855
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)123.82
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.37
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$12.00Price Target Upside318.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
VistaGen Therapeutics News
PremiumCompany Announcements
VistaGen’s Earnings Call: Progress and Challenges
PremiumCompany Announcements
Vistagen Reports Q3 Earnings and Pipeline Progress
PremiumCompany Announcements
VistaGen Reports Q3 2025 Financial Results and Updates
PremiumPre-Earnings
Is VTGN a Buy, Before Earnings?
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe prior PALISADE-2 study was successful, marking VistaGen as the first company to report a positive P3 trial result for a new drug candidate for the acute treatment of SAD.
Pipeline DevelopmentVistaGen introduced PH284, another neuroactive spray in its pipeline, for the treatment of cancer cachexia, and reported positive P2a results.
Bears Say
Financial PerformanceVistaGen reported F3Q25 results with a net loss of ($14.1M).
---
Ownership Overview
1.85% Insiders
7.27% Mutual Funds
38.60% Other Institutional Investors
44.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VTGN FAQ
What was Vistagen Therapeutics Inc.’s price range in the past 12 months?
Vistagen Therapeutics Inc. lowest stock price was $2.22 and its highest was $5.74 in the past 12 months.
What is Vistagen Therapeutics Inc.’s market cap?
Vistagen Therapeutics Inc.’s market cap is $84.71M.
When is Vistagen Therapeutics Inc.’s upcoming earnings report date?
Vistagen Therapeutics Inc.’s upcoming earnings report date is Jul 01, 2025 which is in 130 days.
How were Vistagen Therapeutics Inc.’s earnings last quarter?
Vistagen Therapeutics Inc. released its earnings results on Feb 13, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.51 by $0.05.
Is Vistagen Therapeutics Inc. overvalued?
According to Wall Street analysts Vistagen Therapeutics Inc.’s price is currently Undervalued.
Does Vistagen Therapeutics Inc. pay dividends?
Vistagen Therapeutics Inc. does not currently pay dividends.
What is Vistagen Therapeutics Inc.’s EPS estimate?
Vistagen Therapeutics Inc.’s EPS estimate is -0.51.
How many shares outstanding does Vistagen Therapeutics Inc. have?
Vistagen Therapeutics Inc. has 28,862,085 shares outstanding.
What happened to Vistagen Therapeutics Inc.’s price movement after its last earnings report?
Vistagen Therapeutics Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.51. Following the earnings report the stock price went up 4.211%.
Which hedge fund is a major shareholder of Vistagen Therapeutics Inc.?
Currently, no hedge funds are holding shares in VTGN
---
VistaGen Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (318.12% Upside)
$12.00 (318.12% Upside)
Blogger Sentiment
Bullish
VTGN Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.60%
12-Months-Change
Fundamentals
Return on Equity
-46.28%
Trailing 12-Months
Asset Growth
-29.57%
Trailing 12-Months
Company Description
Vistagen Therapeutics Inc.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
---
VTGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment due to the significant progress in clinical trials, a robust and diverse product pipeline, and a strong financial position. However, increased R&D expenses and net loss were notable concerns.Read More>---
VTGN Stock 12 Month Forecast
Average Price Target
$12.00
▲(318.12% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering VTGN
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-28.01%
reiterated a buy rating 3 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -28.01% per trade.
---